NCT05536154 2024-03-19
Etoposide+Cytarabine+PEG-rhG-CSF as First Line Mobilization Regimen of Hematopoietic Stem Cells in Patients With Hematological Malignancies
The Affiliated People's Hospital of Ningbo University
Phase NA Unknown
Clinical Trials
139 trialsNCT05510089 2023-10-10
Etoposide+Cytarabine+PEG-rhG-CSF for Hematopoietic Stem Cell Mobilization in Patients With Hematological Malignancies
The Affiliated People's Hospital of Ningbo University
Phase NA Unknown
NCT05313958 2023-07-27
SCCLG-M5
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 2/3 Unknown
NCT05863845 2023-05-18
Efficacy and Safety of Venetoclax Combined With BEAM Pretreatment in Autologous Transplantation for DLBCL
Ruijin Hospital
Phase NA Unknown
NCT04217278 2023-05-10
COSI
University of Birmingham
Phase 2/3 Unknown
NCT05805072 2023-05-06
Selinexor and HAAG With/Without HMA in Relapsed/Refractory Acute Leukemia (AML) Patients
The First Affiliated Hospital of Soochow University
Phase NA Unknown
NCT03467256 2023-02-24
CD19 T-CAR for Treatment of Children and Young Adults With r/r B-ALL
Federal Research Institute of Pediatric Hematology, Oncology and Immunology
Phase 1/2 Unknown
NCT04688021 2023-02-21
A Single-arm Trial of Prophylactic Tocilizumab for Acute GVHD Prevention After Haploidentical HSCT.
First Affiliated Hospital of Zhejiang University
Phase 2 Unknown
NCT05665075 2023-01-03
Natural Killer (NK) Cell Therapy Targeting CD33 in Acute Myeloid Leukemia
Zhejiang University
Phase 1 Unknown
NCT05665114 2023-01-03
Natural Killer(NK) Cell Therapy in r/r AML
Zhejiang University
Phase 1 Unknown
NCT05578378 2022-10-13
Cladribine Combined With G-CSF and Cytarabine as a Salvage Treatment in R/R ALL
The First Affiliated Hospital of Soochow University
Phase 2/3 Unknown
NCT04687761 2022-09-08
Clinical Trial to Assess the Safety and Tolerability of the Combination of Low-dose Cytarabine or Azacitidine Plus Venetoclax and Quizartinib in Newly Diagnosed AML Patients Aged Equal or More Than 60 Years Old
PETHEMA Foundation
Phase 1/2 Unknown
NCT05466318 2022-07-25
ChiCGB vs BEAM in High-risk or R/R Lymphomas
Sichuan University
Phase 3 Unknown
NCT03736616 2022-07-22
Acalabrutinib Plus RICE for Relapsed/Refractory DLBCL
Swedish Medical Center
Phase 2 Unknown
NCT03570983 2022-06-22
BEAM
Swedish Medical Center
Phase 2 Unknown
NCT05382390 2022-05-19
Dual Growth Factor (rhTPO + G-CSF) and Chemotherapy Combination Regimen in Acute Myeloid Leukemia: Study Protocol for a Randomized Controlled Trial
Shengjing Hospital
Phase 3 Unknown
NCT05362942 2022-05-05
Combination of Venetoclax, Hypomethylation Agent and Low-dose Cytarabine as a Salvage Therapy for Acute Myeloid Leukemia
Beijing 302 Hospital
Phase 2 Unknown
NCT05053425 2022-04-26
Bcl-2 Inhibitors Combined With Azacytidine and Chemotherapy in Elderly Patients With Previously Untreated AML
LanZhou University
Phase NA Unknown
NCT04112589 2022-03-14
A Clinical Trial to Assess the Efficacy and Safety of the Combination of a Drug Call Quizartinib With Chemotherapy (FLAG-IDA) in Patients With Acute Myeloid Leukemia That Has Not Responded to the First Treatment or That Has Returned After the First Treatment
PETHEMA Foundation
Phase 1/2 Unknown
NCT05258799 2022-02-28
Dual Growth Factor (rhTPO + G-CSF) and Chemotherapy Combination Regimen for Elderly Patients With Acute Myeloid Leukemia: A Phase II Single-Arm Multicenter Study
Shengjing Hospital
Phase NA Unknown
NCT02481310 2022-02-21
Combination Chemotherapy, Rituximab, and Ixazomib Citrate in Treating Patients With Non-Hodgkin Lymphoma
Northwestern University
Phase 1/2 Unknown
NCT03837873 2022-01-26
DLCL002 Protocol for Patients With High Risk Aggressive B-cell Lymphoma
Institute of Hematology & Blood Diseases Hospital, China
Phase 2 Unknown
NCT01358201 2022-01-19
PETHEMA LAL-07FRAIL: All Treatment In Fragile Patients Ph' Negative Over 55 Years
PETHEMA Foundation
Phase 4 Unknown
NCT01366898 2022-01-19
Protocol For the Treatment Acute Lymphoblastic Leukemia With Ph 'Negative in Elderly Patients (> 55 Years)
PETHEMA Foundation
Phase 4 Unknown
NCT03629873 2022-01-03
Efficacy and Safety of Chi-BEAC Combining With Auto-HSCT to Treat Aggressive Lymphoma Subjects
The First Affiliated Hospital with Nanjing Medical University
Phase 2 Unknown
NCT04722952 2021-12-03
PD-1 Inhibitor Combined With Azacytidine and Homoharringtonine，Cytarabine, G-CSF for Refractory or Relapsed AML
The First Affiliated Hospital of Soochow University
Phase 3 Unknown
NCT04716114 2021-11-02
ALIVE
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Phase 3 Unknown
NCT05100303 2021-10-29
A Study to Evaluate the Tolerance and Efficacy of Mitoxantrone Hydrochloride Liposome Injection Combined With Cytarabine in Patients With Acute Myeloid Leukemia (AML)
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Phase 1/2 Unknown
NCT03257241 2021-10-01
PALG-AML1/2016
Polish Adult Leukemia Group
Phase 3 Unknown
NCT05026229 2021-10-01
A Study of Dasatinib Plus Reduced Intensive Consolidation Chemotherapy in Ph+ Adult ALL
First Affiliated Hospital Xi'an Jiaotong University
Phase NA Unknown
NCT05049473 2021-09-20
Treatment of Mature B-ALL and Burkitt Lymphoma (BL) in Adult Patients. BURKIMAB-14.
PETHEMA Foundation
Phase 2 Unknown
NCT00558519 2021-08-18
Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia
Alliance for Clinical Trials in Oncology
Phase 2 Unknown
NCT00651261 2021-08-18
Daunorubicin, Cytarabine, and Midostaurin in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia
Alliance for Clinical Trials in Oncology
Phase 3 Unknown
NCT01296178 2021-03-23
PETHEMA-LMA10: Treatment of Acute Myeloblastic Leukemia (AML) in Patients Less Than or Equal to 65 Years
PETHEMA Foundation
Phase NA Unknown
NCT04254640 2020-12-17
Efficacy and Safety of Cladribine in Combination With CAG in Newly Diagnosed Unfit Patients With AML
Sun Yat-sen University
Phase 2 Unknown
NCT04541277 2020-09-09
Combined Inhibition of PD-1 and DNA Hypomethylating Agent +/- Chemotherapy in High-risk AML or Elderly Patients With AML Who Are Unfit for Intensive Chemotherapy
Chinese PLA General Hospital
Phase 2 Unknown
NCT03417427 2020-04-27
A Clinical Trail of Demethylation Drug Combined With Chemotherapy in Intermediate-risk AML
Nanfang Hospital, Southern Medical University
Phase 2 Unknown
NCT02638428 2020-03-19
Genomics-Based Target Therapy for Children With Relapsed or Refractory Malignancy
Samsung Medical Center
Phase 2 Unknown
NCT04168138 2019-11-19
D-CTAG in the Treatment of Newly Diagnosed Acute Myeloid Leukemia in Elderly Patients
Shengjing Hospital
Phase NA Unknown
NCT04083911 2019-09-10
Study of DAC Combined With HAAG Regimen in Newly Diagnosed AML Patients Older Than 60
The First Affiliated Hospital of Soochow University
Phase 3 Unknown
NCT03181815 2019-08-20
Cladribine in Combination With CAG in Patients With Refractory/Relapsed Acute Myeloid Leukemia
Sun Yat-sen University
Phase 2 Unknown
NCT03318419 2019-08-20
Cladribine in Combination With GAP in Patients With Refractory/Relapsed Acute Lymphoblastic Leukemia
Sun Yat-sen University
Phase 2 Unknown
NCT00550992 2019-07-30
Interfant06
Dutch Childhood Oncology Group
Phase NA Unknown
NCT02717884 2018-10-18
TRANSATRA
University Hospital Freiburg
Phase 1/2 Unknown
NCT01429610 2018-07-24
RADICAL
Asan Medical Center
Phase 2 Unknown
NCT03564704 2018-06-21
Precision Diagnosis Directing HDACi Chidamide Target Therapy for Adult T-LBL/ALL
Nanfang Hospital, Southern Medical University
Phase 2/3 Unknown
NCT03553238 2018-06-12
Precision Diagnosis Directing HDACi Chidamide Target Therapy for Adult ETP-ALL
Nanfang Hospital, Southern Medical University
Phase 2/3 Unknown
NCT02576301 2018-06-04
AML
Mateon Therapeutics
Phase 1/2 Unknown
NCT03315520 2018-05-22
BeEAC-1
State Budgetary Healthcare Institution, National Medical Surgical Center N.A. N.I. Pirogov, Ministry of Health of Russia
Phase 2 Unknown
NCT03381781 2018-01-04
Decitabine,Cytarabine and Arsenic Trioxide for Acute Myeloid Leukemia With p53 Mutations
Ruijin Hospital
Phase 2 Unknown